The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Heparin: Past, Present, and Future
Open accessAbstract
Heparin, the most widely used anticoagulant drug in the world today, remains an animal-derived product with the attendant risks of adulteration and contamination. A contamination crisis in 2007–2008 increased the impetus to provide non-animal-derived sources of heparin, produced under cGMP conditions. In addition, recent studies suggest that heparin may have significant antineoplastic activity, separate and distinct from its anticoagulant activity, while other studies indicate a role for heparin in treating inflammation, infertility, and infectious disease. A variety of strategies have been proposed to produce a bioengineered heparin. In this review, we discuss several of these strategies including microbial production, mammalian cell production, and chemoenzymatic modification. We also propose strategies for creating “designer” heparins and heparan-sulfates with various biochemical and physiological properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Garcia, D. A., Baglin, T. P., Weitz, J. I., & Samama, M. M. (2012) · Chest · doi:10.1378/chest.11-2291 · Cited by 1,091
Heparin and Low-Molecular-Weight Heparin
Hirsh, J., Warkentin, T. E., Raschke, R., Granger, C., Ohman, E. M., & Dalen, J. E. (1998) · Chest · doi:10.1378/chest.114.5_supplement.489s · Cited by 1,031
Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis
Vlodavsky, I., Friedmann, Y., Elkin, M., Aingorn, H., Atzmon, R., Ishai-Michaeli, R., Bitan, M., Pappo, O., Peretz, T., Michal, I., et al. (1999) · Nature Medicine · doi:10.1038/10518 · Cited by 803
The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line
Xu, X., Nagarajan, H., Lewis, N. E., Pan, S., Cai, Z., Liu, X., Chen, W., Xie, M., Wang, W., Hammond, S., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1932 · Cited by 785
Borsig, L., Wong, R., Feramisco, J., Nadeau, D. R., Varki, N. M., & Varki, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061615598 · Cited by 714
Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events
Guerrini, M., Beccati, D., Shriver, Z., Naggi, A., Viswanathan, K., Bisio, A., Capila, I., Lansing, J. C., Guglieri, S., Fraser, B., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1407 · Cited by 628
Self-citationMolecular properties and involvement of heparanase in cancer metastasis and angiogenesis
Vlodavsky, I., & Friedmann, Y. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13662 · Cited by 618
Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation
Nelson, R., Cecconi, O., Roberts, W., Aruffo, A., Linhardt, R., & Bevilacqua, M. (1993) · Blood · doi:10.1182/blood.v82.11.3253.3253 · Cited by 516
Self-citationStructure and Biological Activity of Heparin
Casu, B. (1985) · Advances in Carbohydrate Chemistry and Biochemistry · doi:10.1016/s0065-2318(08)60067-0 · Cited by 428
The anti-inflammatory effects of heparin and related compounds
Young, E. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2006.10.026 · Cited by 390
Cited by
Brestoff, J. R., Wilen, C. B., Moley, J. R., Li, Y., Zou, W., Malvin, N. P., Rowen, M. N., Saunders, B. T., Ma, H., Mack, M. R., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.11.008 · Cited by 397
Carbohydrate-Based Macromolecular Biomaterials
Su, L., Feng, Y., Wei, K., Xu, X., Liu, R., & Chen, G. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01338 · Cited by 335
Glycosaminoglycans from marine sources as therapeutic agents
Valcarcel, J., Novoa-Carballal, R., Pérez-Martín, R. I., Reis, R. L., & Vázquez, J. A. (2017) · Biotechnology Advances · doi:10.1016/j.biotechadv.2017.07.008 · Cited by 188
Metadata
- Authors
- Oduah, E., Linhardt, R., & Sharfstein, S.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2016-07-04
- Volume
- 9
- Issue
- 3
- Pages
- 38
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W2466124353
- Cited by
- 281
- References
- 58
- FWCI
- 10.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Heparin: Past, Present, and Future. https://app.cochat.ai/papers/10.3390/ph9030038
- The paper
- Oduah, E., Linhardt, R., & Sharfstein, S. (2016). Heparin: Past, Present, and Future. Pharmaceuticals. https://doi.org/10.3390/ph9030038
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.